Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
AstraZeneca
Scientific Title
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients With Minimal Residual Disease Following Surgery and Curative Intent Therapy.